Neurogene Inc. heads into its May 15 results carrying two contradictory signals: one of the most bullish options postures in the past year sits alongside a short interest level that still commands nearly a quarter of the free float.
The options market is shouting optimism. The put/call ratio has collapsed to 0.08, its lowest reading in the past 52 weeks and nearly one standard deviation below its 20-day average of 0.14. Call volume is dominating — emphatically — as the stock has climbed 55% in a single month to $31.54, with a further 9% tacked on in the past week alone. Availability in the lending market has eased relative to the April lows, when the borrow pool tightened sharply and cost to borrow briefly touched 1.37%. Both have since loosened: CTB has dropped 34% over the past month to 0.74%, and availability is no longer at crisis levels, suggesting the short covering that trimmed positions by roughly 8% in a single session on May 11 came through without a liquidity crunch.
Short interest still tells a weighty story, however. Roughly 24% of the free float remains short — among the most elevated readings in the broader biotech universe — and the ORTEX short score of 82 ranks in the 98th percentile of all tracked stocks. Days to cover clocks at nearly 20, meaning an orderly unwind would take the better part of a month. That structural overhang is the bear's primary tool. Canaccord Genuity, covering with a Buy, trimmed its price target from $200 to $180 in early April — still implying more than five times the current price. The breadth of that gap warrants caution: with nine analysts holding Buy ratings and a consensus target near $76, the Street sits well above the current price, but the May 12 Q1 EPS print of -$1.39 missed the -$1.36 estimate, a small but real undershoot that arrived just days before the formal earnings event. The company carries a net cash position near $352 million against operating cash burn of roughly $104 million annually — a runway that limits near-term financing panic but does not eliminate dilution risk.
Insider selling has been a quiet counterweight to the bullish tone. The CFO sold shares twice in early May near the $30–$32 range — right where the stock trades today — and the CEO, CSO, and CMO all trimmed in March. None of the transactions were large in dollar terms, but the cluster of c-suite sales into the rally is a pattern worth noting. Among institutional holders, Trails Edge Capital Partners and TD Bank each entered as new holders at year-end, while specialist biotech funds including Samsara BioCapital and RTW have held steady.
The print will test whether the NGN-401 Rett syndrome program's 24-month durability data and expanding trial footprint can anchor a narrative strong enough to justify a stock that has already re-rated sharply — and whether 24% short interest starts moving in earnest in either direction.
See the live data behind this article on ORTEX.
Open NGNE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
